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Summary
 
The cause of many autoimmune and inflammatory diseases is unresolved, although dysregu-
lated production of tumor necrosis factor (TNF) family members appears to be important in
many cases. BAFF, a new member of the TNF family, binds to B cells and costimulates their
growth in vitro. Mice transgenic for BAFF have vastly increased numbers of mature B and ef-
fector T cells, and develop autoimmune-like manifestations such as the presence of high levels of
rheumatoid factors, circulating immune complexes, anti–DNA autoantibodies, and immuno-
globulin deposition in the kidneys. This phenotype is reminiscent of certain human autoim-
mune disorders and suggests that dysregulation of BAFF expression may be a critical element in
the chain of events leading to autoimmunity.
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S
 
elf-reactive B cells constantly emerge during lympho-
poiesis. Fortunately, the immune system has several
powerful means of eliminating or neutralizing autoreactive
B cells, both centrally as they emerge from the stem cell pool
and peripherally as mature B cells undergo somatic muta-
tion (1, 2). Despite the diversity of systems that allow dis-
crimination between self and nonself, failure to eliminate
autoreactive lymphocytes occurs, for instance, in genetically
predisposed individuals, or as a consequence of infection or
cytokine imbalance, leading to autoimmunity (3, 4). Auto-
immune diseases can be divided into three categories, T
cell–dominant, B cell–dominant, or combinational types.
Direct roles for B cells and immunoglobulin production have
also been proposed in autoimmune disorders more tradition-
ally thought to be primarily T cell–mediated, such as rheu-
matoid arthritis (5, 6) and inflammatory bowel disease (7). In
animal models, such involvement can be readily demon-
strated (6, 8, 9).
Most members of the tumor necrosis factor family con-
trol aspects of immune function such as organogenesis of
secondary lymphoid organs (10), lymphocyte activation,
and effective inflammatory/immune responses (11). Inter-
estingly, imbalance in the production of some of these
ligands has been shown to contribute to inflammatory and
autoimmune disorders (12). The Fas/FasL system is proba-
bly the most striking example of a pathway directly in-
volved in the elimination of some subsets of autoreactive B
and T lymphocytes by apoptosis. Mice lacking functional
expression of Fas (
 
lpr
 
) or FasL (
 
gld
 
) develop severe autoim-
mune lymphoproliferative disorders, leading to tissue destruc-
tion (13). Another member of the TNF superfamily, CD30L,
seems to have a role of protection against autoimmunity, as
signaling through its receptor was shown to protect against au-
toimmune diabetes mediated by CD8 T cells (14). More of-
ten, a reverse situation is seen by which abnormal levels
rather than absence of expression directly contributes to the
pathophysiology of autoimmune diseases (12). TNF is the
most extensively studied member of this family, and its par-
ticipation in several autoimmune disorders such as rheuma-
toid arthritis, inflammatory bowel disease, and autoimmune
encephalomyelitis is now well established (15). Participa-
tion or abnormal expression in autoimmune disease has
been described for other ligands of this family such as OX40
(16), CD27 (17), and lymphotoxin (18).
Early studies on the CD40/CD40L pathway revealed
specific roles in B cell biology (19) promoting B cell activa-
tion, proliferation, survival, isotype switching, germinal
center formation, and generation of memory B cells (20). It
was, therefore, not surprising that interrupting this pathway
inhibited disease in rodent models of rheumatoid arthritis
and systemic lupus nephritis, in which B cell tolerance is
severely altered (21, 22). Recent studies have shown that
the role of the CD40/CD40L pathway in disease is not
solely directed towards B cell regulation, but extends to
many other cell types (20).
We have recently identified a new TNF-like ligand,
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called BAFF (for B cell activating factor belonging to the
TNF family),
 
1
 
 which is expressed by dendritic cells and
possibly T cells and binds primarily to B cells (23). BAFF is
secreted from transfected cells and has the potential to act as
a soluble mediator. BAFF was also independently identified
as TALL-1 (24), as THANK, which regulated apoptosis,
NF-
 
k
 
B and c-Jun NH
 
2
 
-terminal kinase in a human myelo-
cytic cell line (25), and, more recently, as BlyS, a factor
that, when administrated to normal mice, disrupted splenic
B and T cell zones and resulted in elevated serum IgM con-
centrations (26). Similar to CD40L, BAFF promotes B cell
proliferation in the presence of an anti–IgM antibody in
vitro (23, 26). We have generated transgenic mice overex-
pressing BAFF under the control of a liver-specific promoter.
These mice have excessive numbers of mature B cells, spon-
taneous germinal center reactions, secrete autoantibodies,
high plasma cell numbers in secondary lymphoid organs,
elevated numbers of effector T cells, and Ig deposition in
the kidney.
 
Materials and Methods
 
Generation of BAFF Transgenic Mice. 
 
A PCR fragment encod-
ing full-length murine BAFF was generated by reverse transcrip-
tion–PCR using previously described sequence information (23).
First strand cDNA was synthesized from mouse lung polyA
 
1
 
(Clontech) using oligo dT according to the manufacturer’s proto-
col (GIBCO BRL). The PCR reaction contained 1
 
3
 
 pfu buffer
(Stratagene Inc.), 0.2 mM dNTPs, 10% DMSO, 12.5 pM primers,
5 units
 
 
 
pfu enzyme (Stratagene Inc.), and the following primers
with Not1 restriction sites 5
 
9
 
-TAAGAATGCGGCCGCGGAA-
TGGATGAGTCTGCAAA-3
 
9
 
 and 5
 
9
 
-TAAGAATGCGGCCGC-
GGGATCACGCACTCCAGCAA-3
 
9
 
. The template was ampli-
fied for 30 cycles at 94
 
8
 
C for 1 min, 54
 
8
 
C for 2 min, and 72
 
8
 
C for
3 min, followed by a 10-min extension at 72
 
8
 
C. This sequence
corresponds to nucleotides 214–1171 of the GenBank file
AF119383. The PCR fragment was digested with Not1 and
cloned into a modified pCEP4 vector (Invitrogen Corp.). The
resulting vector was then digested with Xba1 to remove BAFF
plus the SV40 polyA addition site sequence. This fragment was
cloned into a pUC-based vector in which the promoter, a 1-kb
blunt Bgl2–Not1 fragment containing the human ApoE en-
hancer and AAT (alpha antitrypsin) previously purified from the
plasmid clone 540B (a gift from Dr. Katherine Parker Ponder,
Washington University, St. Louis, MO) was further inserted at
the EcoRV site. An EcoRV/Bgl2 fragment was purified from the
final vector and used for the generation of transgenic mice. The
injected offspring of C57BL/6J female 
 
3 
 
DBA/2J male F1 (BDF1)
mice were backcrossed onto C57BL/6 mice. Techniques of mi-
croinjection and generation of transgenic mice have been previ-
ously described (27). Animal experiments were approved by the
Institutional Animal Care and Use Committee.
 
Analytical Methods. 
 
Serum samples were subjected to reducing
SDS-PAGE analysis using a linear 12.5% gel. MOPC-21 mouse
IgG1 standard antibody was obtained from PharMingen. Total
RNA from mouse liver was prepared and processed for Northern
blot analysis using an isolation kit from Promega Corp. according
to the manufacturer’s guidelines. BAFF transgene-specific mRNA
was detected using a probe spanning the SV40 polyA tail of the
transgene construct and obtained by digestion of the modified
pCEP4 vector with Xba1 and BamH1. The probe recognizes a
1.8–2-kd band corresponding to mRNA from the BAFF trans-
gene. PCR analysis of tail DNA from BAFF transgenic (Tg) mice
used 12.5 pM of the primers 5
 
9
 
-GCAGTTTCACAGCGAT-
GTCCT-3
 
9
 
 and 5
 
9
 
-GTCTCCGTTGCGTGAAATCTG-3
 
9
 
 in a
reaction containing 1
 
3
 
 Taq polymerase buffer (Stratagene Inc.), 0.2
nM dNTPs, 10% DMSO, and 5 U Taq polymerase (Stratagene
Inc.). 719 bp of the transgene was amplified for 35 cycles at 94
 
8
 
C
for 30 s, 54
 
8
 
C for 1 min, and 72
 
8
 
C for 1.5 min, followed by a 10-
min extension at 72
 
8
 
C.
The presence of proteins in mouse urine was measured using
Multistix 10 SG reagent strips for urinalysis (Bayer Corp., Diag-
nostics Division).
 
Cellular Analysis. 
 
Differential white blood cell counts of fresh
EDTA-anticoagulated whole blood were performed with an Abbott
Cell Dyne 3500 apparatus. For FACS
 
®
 
 analysis (Becton Dickinson &
Co.), fluorescein–(FITC), CyChrome™–, and phycoerythrin (PE)-
labeled rat anti–mouse antibodies: anti–B220, anti–CD4, anti–
CD8, anti–CD43, anti–IgM, anti–CD5, anti–CD25, anti–CD24,
anti–CD38, anti–CD21, anti–CD44, anti–MHC class II, anti–
 
l
 
-selectin, and hamster anti–Bcl-2/control hamster Ig kit were pur-
chased from PharMingen. Production of recombinant 
 
Escherichia
coli, 
 
as well as mammalian cell-derived mouse Flag-tagged BAFF,
was performed as previously described for human BAFF (23). All
antibodies were used according to the manufacturer’s specifications.
PBL were isolated by density gradient centrifugation of EDTA-
treated mouse blood over lymphocyte M (Cedarlane). FACS
 
®
 
 anal-
ysis of spleen, bone marrow, and mesenteric lymph nodes was per-
formed effectively as described previously (28).
 
Detection of Total Mouse Ig and Rheumatoid Factors in Mouse Sera
by ELISA Assays.
 
ELISA plates (Corning Glass Works) were
coated overnight at 4
 
8
 
C with a solution of 10 
 
m
 
g/ml goat anti–
total mouse Ig (Southern Biotechnology Associates, Inc.) in 50 mM
sodium bicarbonate buffer, pH 9.6. Plates were washed three
times with PBS/0.1% Tween and blocked overnight with 1%
gelatin in PBS. 100 
 
m
 
l/well of serum serial dilutions or standard
dilutions was added to the plates for 30 min at 37
 
8
 
C. Mouse Ig
were detected using 100 
 
m
 
l/well of a 1-
 
m
 
g/ml solution of an al-
kaline phosphatase (AP)–labeled goat anti–total mouse Ig (South-
ern Biotechnology Associates, Inc.) for 30 min at 37
 
8
 
C. After a
last wash with PBS/0.1% Tween, the enzymatic reaction was de-
veloped using a solution of 10 
 
m
 
g/ml of 
 
p
 
-nitrophenyl phosphate
(Boehringer Mannheim Biochemicals) in 10% diethanolamine.
The reaction was stopped by adding 100 
 
m
 
l of 3 N NaOH/well.
The optical density was measured at 405 nm using a spectropho-
tometer from Molecular Devices. Standard curves were obtained
using purified mouse Ig purchased from Southern Biotechnology
Associates, Inc. In the case of detection of rheumatoid factors, the
plates were coated with normal goat Ig (Jackson ImmunoRe-
search Laboratories, Inc.) instead of goat anti–mouse Ig, and de-
tection of mouse Ig was performed as described above. Detection
of mouse isotypes in the RF assay was done using AP-labeled
goat anti–mouse IgA, IgM, IgG2a, IgG2b, IgG1, and IgG3, as
well as purified mouse IgA, IgM, IgG2a, IgG2b, IgG1, and IgG3
for standard curves (Southern Biotechnology Associates, Inc.). All
statistical comparisons were performed by analysis of variance.
 
Detection of Circulating Immune Complexes and Precipitation of
Cryoglobulins in Mouse Sera.
 
The assay was performed as previ-
 
1
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; BAFF, B cell ac-
tivating factor belonging to the TNF family; BM, bone marrow; BrdU,
5-bromo-2
 
9
 
-deoxyuridine; CIC, circulating immune complexes; ds, dou-
ble stranded; HRP, horseradish peroxidase; MLN, mesenteric lymph
node; MZ, marginal zone; ss, single stranded; Tg, transgenic.
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ously described (29, 30) with the following modifications: ELISA
plates (Corning Glass Works) were coated overnight at 4
 
8
 
C with 5
 
m
 
g/ml of human C1q (Quidel) in 50 mM sodium bicarbonate
buffer, pH 9.6. The plates were washed three times with PBS/
0.1% Tween. 50 
 
m
 
l/well of 0.3 M EDTA was added to the plates
plus 50 
 
m
 
l/well of serum serial dilutions or solutions of known
concentrations of a standard immune complex (peroxidase-mouse
antiperoxidase) from DAKO Corp. The plates were incubated 30
min at 37
 
8
 
C. The plates were washed three times with PBS/0.1%
Tween. Mouse Ig in the immune complexes were detected using
100 
 
m
 
l/well of a 1 
 
m
 
g/ml solution of an AP-labeled goat anti–
mouse Ig (Southern Biotechnology Associates, Inc.) as described
above for the ELISA assays. Cryoglobulins were detected by in-
cubating overnight at 4
 
8
 
C mouse serum diluted 1/15 in water and
precipitates were scored visually.
 
Anti–double- and –single-stranded DNA Assays. 
 
Detection of anti–
single-stranded (ss) DNA antibodies was performed using NUNC-
immuno Plate MaxiSorp plates (NUNC A/S). Plates were coated
overnight at 4
 
8
 
C first with 100 
 
m
 
g/ml methylated BSA (Calbio-
chem Corp.), then with 50 
 
m
 
g/ml grade I calf thymus DNA
(Sigma Chemical Co.) that was previously sheared by sonication,
and finally digested with S1 nuclease. This DNA was used to coat
plates for the anti–double-stranded (ds) DNA assays, but was ad-
ditionally boiled 10 min and chilled on ice before coating plates
for the anti–ssDNA assays. After blocking, serial dilutions of the
serum samples were added and incubated at room temperature
for 2 h. Autoantibodies were detected with goat anti–mouse
IgG-AP (Sigma Chemical Co.) and developed as described above
for the ELISA assays. Standard curves were obtained using
known quantities of anti–DNA mAb 205, which is specific for
both ss- and dsDNA (31).
 
Immunohistochemistry.
 
Frozen sections of spleen and lymph
nodes were subjected to immunohistochemical analysis as previ-
ously described (32). Biotin-labeled antibodies rat anti–B220,
anti–CD11c, and anti–syndecan-1, as well as unlabeled rat anti–
CD4, anti–CD8
 
a
 
, and anti–CD8
 
b
 
 were purchased from Phar-
Mingen. Biotin-labeled peanut agglutinin was obtained from
Vector Laboratories, Inc. Horseradish peroxidase (HRP)–labeled
mouse anti–rat Ig and HRP-streptavidin were purchased from
Jackson ImmunoResearch Laboratories, Inc., and AP-labeled
streptavidin from Southern Biotechnology Associates, Inc. In the
case of immunohistochemistry on kidney tissue to detect Ig dep-
osition, paraffin sections were used, dewaxed, and blocked using
diluted horse serum from Vector Laboratories, Inc., followed by
staining with HRP goat anti–mouse Ig from Jackson Immuno-
Research Laboratories, Inc. Detection was performed as previ-
ously described for frozen sections (32).
 
Results
 
BAFF-Tg Mice. 
 
Full-length murine BAFF was ex-
pressed in transgenic mice using the liver-specific alpha-1
antitrypsin promoter with the APO E enhancer. The full-
length version was chosen with the expectation that BAFF
would be cleaved and act systemically or, if retained in a
membrane-bound form, that local liver-specific abnormali-
ties would be observed, possibly providing functional clues.
We obtained 13 founder mice positive for the BAFF trans-
gene. BAFF overexpression in the liver of transgenic mice
was confirmed by Northern blot analysis (data not shown).
An ELISA assay for murine BAFF is not available; how-
ever, we found that 2% serum from BAFF-Tg mice, but
not from control mice, blocked the binding of mammalian
 
cell-derived mouse soluble Flag-tagged BAFF to BJAB
cells. Moreover, 5% serum from BAFF-Tg mice but not
from control mice increased the proliferation of human B
cells from PBL in the presence of anti–
 
m
 
 (data not shown).
These data suggest that soluble BAFF is present in the blood
of BAFF-Tg mice. In all BAFF-Tg mice examined histo-
logically, the livers showed no abnormalities, indicating that
local overexpression of BAFF did not induce any immuno-
logical or pathological events (data not shown).
 
Expansion of the Peripheral Blood B Cell Compartment in
BAFF-Tg Mice.
 
The transgenic mouse population was
found to have more lymphocytes in the blood when com-
pared with control negative littermates, reaching values as
high as 13,000 lymphocytes/
 
m
 
l of blood (Fig. 1 A). In con-
trast, the number of granulocytes per microliter of blood in
both BAFF-Tg and control mice remained within normal
limits (Fig. 1 A). The elevated lymphocyte levels resulted
from an expanded B cell subset, since FACS
 
®
 
 analysis, us-
ing anti–CD4 and –B220 antibodies, of peripheral blood
cells (PBL) from 18 BAFF-Tg mice issued from six differ-
ent founders showed increased B/T ratios (Fig. 1, B and
C). Likewise, combining the number of lymphocytes per
microliter of blood with the percentage of circulating T
cells, calculation of absolute numbers of CD4 circulating T
cells revealed a 50% reduction of this T cell subset in
BAFF-Tg mice when compared with control mice, and
the same observation was made for the CD8 T cell subset
(data not shown). All peripheral blood B cells from BAFF-
Tg mice had increased MHC class II and Bcl-2 expression
when compared with B cells from control mice (Fig. 1, D
and E, respectively), indicating some level of B cell activa-
tion in PBL of BAFF-Tg mice. T cells in the blood of
BAFF-Tg mice did not express the early activation markers
CD69 or CD25; however, 40–56% of CD4 or CD8 T cells
were activated effector T cells with a CD44
 
hi
 
, 
 
l
 
-selectin
 
lo
 
phenotype versus only 8–12% in control littermates (Fig.
1 F). Thus, BAFF-Tg mice clearly show signs of an ex-
panded peripheral blood B cell compartment and global B
cell activation along with T cell alterations.
 
Expanded B Cell Compartments Are Composed of Mature
Cells. 
 
To see whether overexpression of BAFF in the
transgenic mice was affecting the B cell compartment cen-
trally in the bone marrow and peripherally in secondary
lymphoid organs, we examined the spleen, bone marrow
(BM), and mesenteric lymph nodes (MLN) from a total of
seven BAFF-Tg mice and seven control littermates derived
from four different founder mice by FACS
 
®
 
 analysis. The
mature B cell compartment was analyzed by dual staining
with anti–B220 and –IgM antibodies. Two representative
BAFF-Tg mice and one control littermate are shown in
Fig. 2. The mature B cell compartment (IgM
 
1
 
/B220
 
1
 
) was
increased in both the spleen and the MLN (Fig. 2 A, top
and bottom panels, respectively). Analysis of B220
 
1
 
/IgM
 
1
 
B cells (Fig. 2 A, middle) or the proB cell (CD43
 
1
 
/B220
 
1
 
)
and the preB cell (CD43
 
2
 
/B220
 
1
 
) compartments in the
BM (Fig. 2 B) showed that BAFF-Tg mice and control lit-
termates were similar. The slight difference in the mature B
cell percentage seen in Fig. 2 A (middle) was not consistent
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Figure 1 (continues on facing page).
 
in all seven mice analyzed. These data indicate that over-
expression of BAFF is affecting the mature B cell com-
partment in the periphery, but not progenitor B cells in
the BM.
We calculated the total number of B and T cells in the
spleen, BM, and MLN (Table I). The total number of B
cells was at least sevenfold higher in the spleen and MLN of
BAFF-Tg mice. The total number of T cells was also in-
creased twofold in the spleen and MLN of these mice (Ta-
ble I). Total numbers of B and T cells in the BM in BAFF-Tg
mice were similar to that of control mice (Table I). The
population of CD5
 
1
 
 B1 cells in the spleen, BM, and peri-
toneal lavages of BAFF-Tg mice was similar to that of con-
trol mice and only marginally increased in MLN (data not
shown).
Analysis by FACS
 
®
 
 of B cell subpopulations in the spleen
revealed an increased proportion of marginal zone (MZ) B
cells in BAFF-Tg mice when compared with control mice
(Table II). The population of follicular B cells remained
equivalent in both BAFF Tg and control mice, whereas the
fraction of newly formed B cells was slightly decreased in
BAFF-Tg mice (Table II). This result was also confirmed
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on B220
 
1
 
 splenic B cells using anti–CD38 vs. anti–CD24
antibodies or anti–IgM vs. anti–IgD antibodies and analyz-
ing the CD38
 
hi
 
/CD24
 
1
 
 and IgM
 
hi
 
/IgD
 
lo
 
 MZ B cell popu-
lation, respectively, as previously described (33) (data not
shown). Immunohistochemical analysis using an anti–mouse
IgM antibody revealed the expansion of the IgM-bright
MZ B cell area in the spleen of BAFF-Tg mice when com-
pared with control mice (data not shown). All BAFF-Tg
Figure 1. Increased B cell numbers in BAFF-Tg mice. (A) Increased lymphocyte counts in BAFF-Tg mice. The graph compares 12 control littermates
(left) with 12 BAFF-Tg mice (right). Lymphocyte counts (s) and granulocytes (including neutrophils, eosinophils, basophils; e) are shown. (B) In-
creased proportion of B cells in PBL from BAFF-Tg mice. PBL were stained with both anti–B220-FITC and anti–CD4-PE for FACS® analysis and gated
on live cells using the forward and side scatter profile. Percentages of CD4- and B220-positive cells are indicated. One control mouse (left) and two
BAFF-Tg mice (right) are shown and the results were representative of seven animals analyzed in each group. (C) FACS® analysis of the ratio of B to T cells
in PBL. The difference between control animals and BAFF-Tg mice in A and C was statistically significant (P , 0.001). (D) Increased MHC class II ex-
pression on B cells from BAFF-Tg mice PBL. MHC class II expression was analyzed by FACS®. (E) Increased Bcl-2 expression in B cells from BAFF-Tg
mice PBL. Bcl-2 expression was measured by intracytoplasmic staining and cells were analyzed by FACS®. In both D and E, B220-positive cells were
gated. Four control littermates (white bars) and four BAFF-Tg mice are shown and are representative of at least 12 animals analyzed for each group. MFI,
mean of fluorescence intensity. The dotted line represents the average MFI for the control animals. The difference between control animals and BAFF-Tg
mice was statistically significant (P , 0.005). (F) Increased expression of effector T cells in BAFF-Tg mice. PBL were stained with anti–CD4-CyChrome™,
anti–CD44-FITC and anti–l-selectin-PE. Shown are CD41-gated cells. Percentages of CD44hi/l-selectinlo cells are indicated. One control mouse (left)
and two BAFF-Tg mice (right) are shown and the results were representative of eight animals analyzed in each group.
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Figure 2. Increased proportion of B cells in the spleen, MLN, but not in the bone marrow of BAFF-Tg mice. (A) FACS® staining for mature B cells using
both anti–IgM-FITC and anti–B220-PE, in spleen (top), bone marrow (middle), and MLN (bottom). Percentages of B2201/IgM1 mature B cells are indi-
cated. (B) FACS® staining for pre–B cells (B2201/CD432) and pro–B cells (B2201/CD431) in the bone marrow using anti–CD43-FITC, anti–B220-
CyChrome™, and anti–IgM-PE simultaneously. Shown are cells gated on the IgM negative population. Percentages of pre–B cells (B2201/CD432) and
pro–B cells (B2201/CD431) are indicated. For all panels (A and B), one control mouse (left) and two BAFF-Tg mice (right) are shown and results are
representative of seven animals analyzed for each group.
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B2201 splenic B cells also expressed higher levels of Bcl-2
(data not shown) and also MHC class II (Table II) com-
pared with splenic B cells from control mice, indicating
that splenic B cells as well as peripheral blood B cells are in
an activated state. At equal cell concentration, splenocytes
isolated from BAFF-Tg mice survived longer in culture
medium when compared with control splenocytes and the
thymidine incorporation after 6 d of culture relative to the
incorporation on day 0 was only decreased 20% in cultures
with BAFF-Tg–derived splenocytes vs. 60% reduction with
control splenocytes (data not shown). In vivo 5-bromo-29-
deoxyuridine (BrdU) incorporation for 4 d did not reveal
any higher BrdU intake in BAFF Tg–splenic B cells when
compared with control mice (data not shown).
BAFF-Tg Mice Have Enlarged B Cell Follicles, Numerous
Germinal Centers, and Reduced Dendritic Cell Numbers and
Increased Plasma Cell Numbers in Both the Spleen and MLN.
BAFF-Tg mice had large spleens (Fig. 3 A), Peyer’s patches
(B), and lymph nodes (C). Immunohistochemistry showed
the presence of enlarged B cell follicles and reduced periar-
Table I. Total Number of T and B Cells in the Spleen, Mesenteric Lymph Nodes, and Bone Marrow
Mouse number
Number of B cells (3107) Number of T cells (3107)
Spleen BM* MLN Spleen BM* MLN
BAFF-Tg mice
816-8-34 18 4 1.4 3.5 0.4 1.1
802-43 34 1.3 5.6 3.5 0.15 1.7
823-3-23 16 3.1 3 3.8 0.46 3.6
802-41 46 3 5 5.3 0.3 0.9
816-1-29 23 1.4 1.2 4 0.07 0.3
Mean 6 SD 27.4 6 11 2.6 6 1.04 3.2 6 1.8 4 6 0.6 0.28 6 0.14 1.5 6 1.2
Control littermates
816-1-20 4.9 3.5 0.12 1.8 0.15 0.27
802-51 7 2.6 0.26 3.1 0.08 0.61
823-2-3 5.5 1.3 0.33 3 0.14 0.05
823-2-6 2.3 1.6 0.1 1.5 0.23 0.3
816-1-24 3.9 1.9 0.17 1.9 0.21 0.32
Mean 6 SD 4.7 6 1.5 2.2 6 0.8 0.19 6 0.08 2.2 6 0.6 0.16 6 0.05 0.31 6 0.2
Controls/BAFF-Tg
P values P , 0.01 P . 0.1 P , 0.01 P , 0.01 P . 0.1 P , 0.05
*Bone marrow was extracted from two femurs. P values were obtained using ANOVA.
Table II. Increased MHC Class II Expression on B Cells and Enlarged Proportion of MZ B Cells in the Spleen of BAFF-Tg Mice
Levels of MHC class II 
expression on B2201 
B cells (MFI)
Percentage of 
follicular B cells*
Percentage of 
MZ B cells‡
Percentage of newly
formed B cells§
Control mice
816-1-10 1170 45 6 12
802-21 1029 48 10.5 9
823-1 1240 39 9 6.5
BAFF-Tg mice
802-6 1707 49 18 5.9
820-7 1900 39 23 6.3
816-1-1 2088 40 23 5.8
Splenocytes were analyzed by FACS® and gated on the B2201 population. A representative experiment is shown. MFI, mean of fluorescence intensity.
*B2201/IgMlo/CD21int.
‡B2201/IgMhi/CD21hi.
§B2201/IgMhi/CD21lo. 
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teriolar lymphocyte sheath (or T cell area) in BAFF-Tg
mice (Fig. 4 B). Interestingly, few germinal centers were
observed in nonimmunized control littermates (and is typi-
cal of this colony in general) and those present were small
(Fig. 4 C), whereas BAFF-Tg mice possessed numerous
and large germinal centers in the absence of immunization
(Fig. 4 D). Staining with anti–CD11c for dendritic cells in
the T cell zone and the marginal zone of control mice (Fig.
4 E) was considerably reduced in BAFF-Tg mice (Fig. 4 F).
Syndecan-1–positive plasma cells were almost undetectable
in the spleen from control littermates (Fig. 4 G), yet the red
pulp of BAFF-Tg mice was strongly positive for synde-
can-1 (Fig. 4 H). Very similar observations were made with
MLN (Fig. 5). In the MLN of BAFF-Tg mice, the B cell
areas were dramatically expanded (Fig. 5 B), in contrast to
the normal appearance, where B cell follicles were easily
recognizable at the periphery of the node under the capsule
with a typical paracortical T cell zone (Fig. 5 A). The me-
dulla of MLN from BAFF-Tg mice were filled with synde-
can-1–positive cells that presumably are plasma cells (Fig. 5
H). Therefore, analysis of secondary lymphoid organs in
BAFF-Tg mice was consistent with the expanded B cell com-
partment seen by FACS® analysis and indicates multiple
cellular abnormalities and intense immune activity.
Figure 3. Enlarged spleen, Peyer’s patches, and lymph nodes in BAFF-Tg
mice. Photograph of (A) spleen, (B) Peyer’s patches (indicated with an
arrow) on the small intestine, and (C) inguinal lymph nodes of a control
mouse (right) and two BAFF-Tg mice (left). Pictures (53) are representa-
tive of at least 12 mice killed for each group.
Figure 4. Altered T and B cell organization, intense germinal center
reactions, decreased number of dendritic cells, and increased number of
plasma cells in the spleen of BAFF-Tg mice. A control mouse is shown in
A, C, E, and G and a BAFF-Tg mouse in B, D, F, and H. B cells are blue
and T cells brown (A and B). Germinal centers are marked with an arrow
(C and D). Only a few residual germinal centers are seen in control mice
(C). CD11c-positive dendritic cells are brown and appear in the T cell
zone, bridging channels and the marginal zone (E). Very few are present
in BAFF-Tg mice (F). Syndecan-1–positive plasma cells were only detect-
able in the red pulp of BAFF-Tg mice (H) but not control mice (G).
These pictures are representative of at least 12 BAFF-Tg mice analyzed
and 12 control mice. 1003 except C and D (503). B, B cell follicle; T,
periarteriolar lymphocyte sheath; WP, white pulp; RP, red pulp.
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BAFF-Tg Mice Have High Levels of Total Immunoglobulins,
Rheumatoid Factors, and Circulating Immune Complexes in Their
Serum. The increased B cell compartment in BAFF-Tg
mice suggested that the level of total Ig in the blood of
these animals might also be increased. SDS-PAGE analysis
of the serum showed that IgG levels were elevated in all
BAFF-Tg mice, while the nontransgenic littermates dis-
played a normal pattern of serum proteins (Fig. 6 A). By
comparison with an IgG1 standard antibody, the levels of
IgG in a nontransgenic mouse were z5–8 mg/ml, and
these levels increased to at least 50 mg/ml in some BAFF-
Tg mice (quantification was done with underloaded gels).
In normal mice, the light chain band is smeared due to the
polyclonal nature of the Ig and on this basis the elevated Ig
levels in BAFF-Tg mice were also polyclonal in nature.
IgM levels were visibly increased in these mice, albeit not
as much as IgG, and this band is seen as a smear on top of a
transferrin band in this gel.
High serum Ig levels in BAFF-Tg mice were confirmed
by ELISA (Fig. 6 B), and the high levels of Ig seen in these
mice led us to suspect the presence of rheumatoid factors,
or autoantibodies directed against antigenic determinants
on the Fc domain of IgG (34). These antibodies could bind
to the goat anti–mouse Ig used to coat the ELISA plates
and give erroneously high values. ELISA plates were,
therefore, coated with normal goat Ig and the binding of
BAFF Tg Ig to normal goat Ig was measured. Fig. 6 C
shows that sera from most BAFF-Tg mice contained Ig re-
acting with normal goat Ig, whereas only 2 of 19 control
mice exhibited reactivity in the same assay. These RF were
mainly of the IgM, IgA, and IgG2a isotypes (data not
shown).
Presence of RF can be associated with the presence of
high levels of circulating immune complexes (CIC) and
cryoglobulin in the blood (34). To verify whether or not
BAFF-Tg mice have abnormal serum levels of CIC, a C1q-
based binding assay was used to detect CIC in the 21 BAFF-
Tg mice analyzed above. Only five BAFF-Tg mice showed
significantly high levels of CIC when compared with control
mice; nonetheless, these mice corresponded to the animals
having the highest total serum Ig and rheumatoid factor lev-
els (Fig. 6 D). We also observed precipitate formation when
sera from BAFF-Tg mice, but not control sera, were diluted
1/15 in water, indicating the presence of cryoglobulin in
these mice (data not shown). Thus, in addition to B cell hy-
perplasia, BAFF-Tg mice display severe hyperglobulinemia
associated with the presence of RF and CIC.
Some BAFF-Tg Mice Have High Levels of Anti–ss and –dsDNA
Autoantibodies, Ig Deposition in the Kidneys, and Proteinuria.
Initially, we observed kidney abnormalities reminiscent of a
lupus-like disease in two of our founder mice. The presence
of anti–DNA autoantibodies has also been described in
SLE patients or the SLE-like (SWR 3 NZB)F1 (SNF1)
mouse (31). Anti–ssDNA autoantibody levels were detected
in BAFF-Tg mice previously shown to have the highest level
of total serum Ig (Fig. 7 A). We analyzed the serum of two
BAFF-Tg mice negative for antibodies against ssDNA (697-5
and 816-1-1) and three transgenic mice secreting anti–ssDNA
antibodies (820-14, 816-8-3, and 820-7) for the presence of
anti–dsDNA antibodies in parallel with five control litter-
mates. BAFF-Tg mice also secreted anti–dsDNA; however,
the levels of secretion did not always correlate with that of
anti–ssDNA antibodies, as serum from BAFF-Tg mouse
697-5, which did not contain detectable levels of anti–ssDNA
antibodies, was clearly positive for the presence of anti–
dsDNA (Fig. 7 B). Therefore, BAFF-Tg mice showing the
most severe hyperglobulinemia secrete high levels of anti–
DNA autoantibodies. Additionally, and also reminiscent of
lupus-like nephritis, we detected immunoglobulin deposition
in the kidney of six BAFF-Tg mice analyzed (Fig. 7 C), three
of these mice did not secrete detectable levels of anti–DNA
antibodies (data not shown). All BAFF-Tg mice have pro-
teinuria (Table III). Sera from all BAFF-Tg mice, but not
control mice, diluted 1/100, stained the nuclei of lymph node
cells on tissue sections, indicating the presence of antinuclear
antibodies in the serum of BAFF-Tg mice (data not shown).
Figure 5. Disrupted T and B cell organization, intense germinal center
reactions, and large numbers of plasma cells in the MLN of BAFF-Tg
mice. The control mouse is shown in A, C, E, and G and the BAFF-Tg
mouse is shown in B, D, F, and H. The immunohistochemistry was per-
formed as described in Fig. 6. T and B cell staining is shown in A and B,
germinal centers in C and D, dendritic cells in E and F, and plasma cells
in G and H. The background is slightly more intense in C, but no germi-
nal centers were detectable. GC, germinal center. Original magnifications:
3100.
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Discussion
BAFF is a powerful cytokine affecting B cells, and has
consequences for T cell and dendritic cell status. The nature
of the expanded B cell subset in BAFF-Tg mice is still un-
clear, but seems to be restricted to mature B cells that have
been activated. Overexpression of BAFF led to the emer-
gence of autoimmune manifestations such as production of
autoantibodies, proteinuria, Ig deposition in kidneys, and in-
tense germinal center formation. Thus, BAFF ligand and its
receptor on B cells form a novel immunoregulatory system.
Whether a ligand is secreted or membrane-bound has
profound biological ramifications. These mice were de-
signed to express high levels of BAFF in the liver and,
while it cannot be excluded that low level of expression
somewhere in the immune system accounts for this unusual
biology, we view it more likely that BAFF is secreted from
the liver and acts at a distant site. We have indirect evidence
for the presence of BAFF in the serum of transgenic mice
and, moreover, injection of recombinant BAFF in normal
mice led to some of the effects described here (26). Well-
defined secretion of a TNF family ligand with functional
consequences in vivo has been observed only infrequently;
e.g., TNF and lymphotoxin-a. BAFF, TWEAK, and APRIL
are three relatively new ligands that possess canonical furin
cleavage motifs in the stalk region and are readily secreted
from transfected cell systems (23, 35, 36). Whether such se-
cretion in vitro actually predicts for a soluble ligand system
is not clear, yet this BAFF-Tg mouse would indicate that
secretion can occur at least from the liver and, thus, soluble
BAFF ligand is capable of mediating biological events in
vivo. Alternatively, facile cleavage may represent a mecha-
nism that ensures a very transient localized signaling event.
The in vitro analysis using recombinant soluble BAFF
protein showed that BAFF costimulated B cell growth in
conjunction with B cell receptor activation, yet by itself it
did not stimulate proliferation of resting B cells (23). If
BAFF is truly a soluble mediator, then this observation is
similar to that made originally for IL-2 and T cell growth,
and prompts the question of whether BAFF is a B cell
growth factor. The present data do not allow one to distin-
guish between a costimulatory action (e.g., analogous to
the activity of CD28) and a true B cell growth factor-like
activity. Regardless of the mechanism, these data suggest
that expansion of the B cell compartment in these mice is
the result of BAFF-induced proliferative stimuli, yet nega-
tive results with 4 d in vivo BrdU incorporation and in-
creased ex vivo survival of splenocytes raised the possibility
dilution of the sera giving an OD three times higher than that of back-
ground. The quantity of CIC is defined as the quantity of peroxidase-
mouse antiperoxidase required to generate an OD equivalent to that ob-
tained with the tested serum. The difference between control animals and
BAFF-Tg mice was statistically significant (P , 0.001 in B and C, P ,
0.003 in D).
Figure 6. Increased Ig, RF, and CIC levels in BAFF-Tg mice. (A) Re-
duced SDS-PAGE of sera from five control littermates and nine BAFF-
Tg mice showing that BAFF increases IgG levels. For comparison, mouse
IgG1 (MOPC-21) was included as a standard: loading per lane was 5 mg
of MOPC-21 and 0.5 ml of the serum. The sharp band slightly below the
Ig light chain is not an immunoglobulin and the IgM heavy chain comi-
grates with transferrin. ELISA-based analysis of total mouse Ig (B), RF
(C), and CIC (D) in the sera of 19 control littermates (white bars) and 21
BAFF-Tg mice (black bars). The titer (log base 2) for RF is defined as the
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that this observation stems from an increased output from
the bone marrow and/or a decreased death rate.
The CD40 pathway clearly plays a major role in B cell
regulation, inviting a comparison with the BAFF system.
An increase in the size of the B cell population, enlarged
spleens, lymph nodes, and Ig deposition in the kidney were
also observed in CD40L-Tg mice (37). Several aspects
clearly distinguish these two mice; for example, CD40L-Tg
mice develop inflammatory bowel disease (IBD), which
was not observed in BAFF-Tg mice, and the alterations in
the organization of the secondary lymphoid organs are very
different (37). In CD40L-Tg mice, but not BAFF-Tg
mice, the organization of the thymus is altered, which pre-
sumably impairs proper T cell selection leading to IBD, as
seen in other mouse models with thymic disfunction (38).
The difference between these two transgenic mice may
Figure 7. Presence of anti–ssDNA
and –dsDNA autoantibodies in some
BAFF-Tg mice, and Ig deposition in
the kidneys. (A) Analysis by ELISA of
anti–ssDNA autoantibodies in 19 con-
trol littermates (left) and 21 BAFF-Tg
mice (black bars). (B) Analysis by
ELISA of anti–ssDNA autoantibodies
in five control littermates and the five
animals showing levels of anti–ssDNA
autoantibodies from A (black bars). (C)
Paraffin sections of kidneys from a con-
trol mouse (left) and a BAFF-Tg
mouse (right), stained with goat anti–
mouse Ig HRP. Ig deposition is shown
by a brown staining. These pictures are
representative of six BAFF-Tg mice
analyzed. Original magnifications.
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be due in large part to the distinct distribution of these
two ligands and their corresponding receptors. Transgene-
expressed CD40L is a membrane-bound ligand primarily ex-
pressed on thymocytes and activated T cells, whereas trans-
genic liver-expressed BAFF has the characteristic of a soluble
ligand and, therefore, can diffuse into multiple compartments.
CD40 is expressed on a wide variety of cell types (20),
whereas expression of BAFF receptor is restricted to B cells
and possibly monocytic cells (23–26). Given the disparate
phenotypes of the BAFF- and CD40L-Tg mice, it is fair to
predict that BAFF and CD40L probably play distinct roles
in normal animals as well. Our results on splenic architec-
ture and elevated Ig levels in the serum of BAFF-Tg mice
are consistent with those described in a recent study using
short-term injection of soluble BAFF in normal mice (26)
and tend to minimize possible developmental disturbances
related to the expression of the BAFF transgene in our
mice. However, chronic exposure of the transgenic mice
to BAFF led to changes not paralleled in mice injected for
4 d with recombinant BAFF (26). In both cases, serum IgM
levels were elevated, yet the BAFF-Tg mice exhibited
vastly increased IgG and IgA levels. The effects of short-
term injections were interpreted as possibly stemming from
activation of T-independent B cell events, whereas here the
elevated IgG and IgA levels, the presence of non-IgM RF
isotypes, and the extensive germinal center formation clearly
indicate ongoing T cell–dependent B cell events.
It is unclear at this point whether BAFF induces the ex-
pansion of both naive and activated B cells, as all B cells in
these mice exhibit elevated expression of both MHC class
II and Bcl-2 and hence show signs of activation. In prelim-
inary experiments, anti–SRBC antibody titers after primary
immunization were similar in BAFF-Tg mice and control
littermates, suggesting that the original pool of naive SRBC-
specific B cells was not expanded compared with that of
control mice. In contrast, SRBC-specific IgG levels after a
secondary response to SRBC were significantly higher in
BAFF-Tg mice when compared with control mice (data
not shown). This result supports a model where BAFF in-
duces the proliferation and/or survival of B cells that had
received an activating B cell receptor signal and this effect
might only be detectable after secondary immunization or
long-term monitoring of the immune response. The en-
larged proportion of MZ B cells in the spleen is interesting
as these cells are described as B cells in an activated state
(39) and as such may be preferential targets for BAFF-
induced proliferative/survival signals. Since the MZ contains
memory B cells (40), it is conceivable that memory B cells
may be specific responders to BAFF-induced signals; this
interpretation would be consistent with the stronger sec-
ondary response seen with SRBC in BAFF-Tg mice. Ad-
ditional experiments will be required to define this aspect
accurately. These results also raise the fundamental question
of the physiological role of BAFF in normal individuals,
and whether examining its function may answer remaining
questions such as the nature of the mechanisms governing
differentiation of B cells into plasma cells vs. germinal cen-
ter B cells or plasma cells vs. memory B cells.
Among the increased B cell populations in BAFF-Tg
mice are emerging autoreactive B cells, secreting RF and
anti–DNA autoantibodies. It is well known that tolerance
to self antigens is never complete and autoreactive B cells,
as well as low levels of rheumatoid factors, can be detected
in normal individuals (3). These autoreactive B cells are re-
ferred to as natural autoreactive B cells. Therefore, one
possibility in BAFF-Tg mice is that the emergence of a
large number of autoreactive B cells may reflect the expan-
sion of occasional natural autoreactive B cells in response to
BAFF-proliferative stimuli. If this was the case, one would
predict that only higher levels of IgM RF would be de-
tected (34), yet high levels of IgA and IgG2a RF were ob-
served indicating isotype switching in the RF-specific B
cells. RF other than IgM are found in patients with auto-
immune diseases such as rheumatoid arthritis (34). There-
fore, the population of RF-specific autoreactive B cells in
BAFF-Tg mice is not only expanded but also activated, in-
dicating a dynamic antigen-specific process leading to au-
toimmune manifestations rather than passive expansion. It
cannot be excluded that BAFF-Tg mice have larger num-
bers of nonnatural self-reactive B cells that have not been
identified or possibly larger numbers of foreign antigen-
specific activated B cells.
A number of studies have shown that the escape of au-
toreactive B cells from clonal deletion or functional inacti-
vation (clonal anergy) alone is not enough to develop auto-
immune disease (1, 41). Additional factors such as infection,
cytokines, and costimulatory help from T cells are required.
The presence of large germinal centers in secondary lym-
phoid organs of BAFF-Tg mice, higher total T cell num-
bers in the spleen and MLN, as well as the increased pro-
portion of both CD4 and CD8 effector T cells in the
periphery, and the quality of the RF isotypes strongly sug-
gest the active participation of T cells in the immune reac-
tions triggered in BAFF-Tg mice. Whether the enlarged
population of activated effector T cells contains autoreac-
tive T cells remains to be determined. One may question
Table III. Levels of Proteinuria* in BAFF-Tg Mice
Control littermates BAFF-Tg mice
816-1-20 2 802-43 111
802-51 1 823-3-23 111
823-2-3 1/2 816-1-33 111
823-2-6 2 816-1-29 1111
816-1-24 2 802-11 111
802-64 2 802-13 1111
802-68 2 802-27 111
823-14-13 2 816-6-2 111
823-14-19 1/2 816-8-15 111
816-6-4 1 816-8-20 11
*Proteinuria was measured using medical color strips dipped in mouse
urine and is defined as follows: 2, no proteinuria; 1/2, trace; 1, 30
mg/dl; 11, 100 mg/dl; 111, 300 mg/dl; 1111, .2,000 mg/dl.
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why BAFF-Tg mice do not show more severe pathological
manifestations. Potential explanations include the expres-
sion of nonlethal BAFF levels in surviving BAFF-Tg founders,
the absence of either pathogenic B cells or tissue-destruct-
ing antibodies as seen in some murine models of lupus and
rheumatoid arthritis, respectively (6, 42) and, finally, the
H-2b background of the BAFF-Tg mice, which may not
favor the emergence of severe autoimmune manifestations.
If overexpression of BAFF indeed initiates an active au-
toimmune reaction in our transgenic mice, we need to
question why tolerance to self has failed. Downregulation
of Bcl-2 expression in autoreactive B cells has been shown
to be one way to sensitize these cell to cell death signals
(43). B cells in BAFF-Tg mice express higher levels of Bcl-2,
indicating a possible protection against apoptotic signals,
and also suggesting that BAFF, like CD40L, provides sur-
vival signals to B cells. One can speculate that this event
coupled with a BAFF proliferative signal may explain the
accumulation of autoreactive B cells in these mice. How-
ever, these changes alone are probably not sufficient to
generate an autoreactive response and one potential answer
may reside in the role of T cells. Increased numbers of ef-
fector T cells were directly observed in the periphery and
there was an apparent reduction in the numbers of den-
dritic cells in the spleen of BAFF-Tg mice. Dendritic cells
are believed to be essential for T cell tolerance to self (44),
and their deficit in BAFF-Tg mice may promote the emer-
gence of autoreactive T cells. Thus, we hypothesize that the
role of BAFF overexpression in impairing self-tolerance
may rely on two mechanisms: promoting enhanced sur-
vival and proliferation of activated autoreactive B cells and
suppression of the protective effects of dendritic cells against
the emergence of autoreactive T cells.
These experiments demonstrate that ectopic overexpres-
sion of BAFF was sufficient to initiate the expansion of the
mature B cell compartment, resulting in lupus-like autoim-
mune manifestations. This transgenic mouse model poten-
tially brings new insight into the etiology of autoimmune
disorders, provides a novel framework for the investigation
of autoreactivity, and potentially opens the door to new
therapeutic strategies both for the treatment of some autoim-
mune disorders and the stimulation of humoral responses.
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